儿童脑肿瘤的表观遗传学与生存者结局
本文综述儿童脑肿瘤中表观遗传机制对肿瘤发生及生存者治疗相关后遗症的影响。重点讨论胶质母细胞瘤、髓母细胞瘤及神经纤维瘤病1型的表观遗传生物标志物,指出其可能作为总生存预后指标及认知等治疗反应指标,但相关研究仍匮乏。
要点
- 表观遗传修饰可沉默抑癌基因并激活驱动基因,参与儿童脑肿瘤发生。
- 表观遗传标志物有望预测儿童脑肿瘤患者总生存及治疗相关后遗症。
- 表观遗传与神经认知等生存者结局的关联研究仍严重不足。
核心结论
- 表观遗传生物标志物有潜力作为儿童脑肿瘤患者总生存的预后指标,并有望指示神经认知等治疗反应。
研究设计与样本
- 综述,聚焦胶质母细胞瘤、髓母细胞瘤及神经纤维瘤病1型,探讨表观遗传因素与生存者结局及治疗的关系。
主要发现
- 表观遗传机制在不同类型脑肿瘤中参与抑癌基因沉默和驱动基因激活。
- 儿童脑肿瘤的表观遗传修饰可能影响长期生存并细化对治疗所致后遗症的分子反应。
- 关于儿童脑肿瘤表观遗传与神经认知及其他治疗相关后遗症关联的研究匮乏。
临床怎么用
- 关注胶质母细胞瘤、髓母细胞瘤及神经纤维瘤病1型的表观遗传标志物作为预后与治疗反应指标的潜力。
局限性
- 缺乏儿童脑肿瘤表观遗传与神经认知及治疗相关后遗症关联的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Brain tumors make up over a quarter of pediatric malignancies. Depending on the age of presentation and treatment, pediatric brain tumor survivors experience varying degrees of treatment induced morbidity and sequelae. Epigenetic mechanisms play a critical role in silencing of tumor suppressor genes and activation of driver genes involved in oncogenesis in different types of brain tumors. Epigenetic modifications in pediatric brain tumor patients may influence long-term survival and may refine the molecular response to treatment induced morbidity and sequelae. However, there is a dearth of studies on how epigenetics of pediatric brain tumors is connected with neurocognition and other treatment related sequelae in survivors. METHODS/RESULTS: In this review we explore epigenetic factors that may contribute to the survivorship and treatment of pediatric brain tumor patients. We focus on glioblastoma, medulloblastoma, and the neurocutaneous syndrome neurofibromatosis type-1 to highlight epigenetic biomarkers that can potentially serve not only as prognostic indicators of overall patient survival, but hopefully as indicators to the response to treatment neurocognitively and otherwise. CONCLUSIONS: Future studies will hopefully soon bridge the gap in our knowledge on how epigenetic modifications are linked to treatment related sequelae in pediatric brain tumor patients.
引用
- Bhattacharya D, Pomeroy SL, Pomeranz Krummel DA, et al. Epigenetics and survivorship in pediatric brain tumor patients. J Neurooncol. 2020. PMID: 32451770. doi:10.1007/s11060-020-03535-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。